Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process. External Web Site Icon Salvador Monalyn U et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Jan JCO1800696

Specific PHGKB|Cancer|PHGKB

Colorectal Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Feb 07, 2019

---

• Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process.  
  Salvador Monalyn U et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Jan JCO1800696
• Advances in Identification of Susceptibility Gene Defects of Hereditary Colorectal Cancer.  
  Liu Qiang et al. Journal of Cancer 2019 10(3) 643-653
• Back to the Colorectal Cancer Consensus Molecular Subtype Future.  
  Menter David G et al. Current gastroenterology reports 2019 Jan 21(2) 5
• Circulating tumor DNA detection: A potential tool for colorectal cancer management.  
  Li Huizi et al. Oncology letters 2019 Feb 17(2) 1409-1416
• Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic.  
  Ghatalia Pooja et al. Frontiers in oncology 2018 8652
• Genetic Analysis Using a Gene Panel in 87 Caucasian Patients With Colorectal Cancer: Own Results and Review of Literature.  
  Smolle Maria A et al. Anticancer research 2019 Feb 39(2) 847-852
• Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?  
  Nichetti Federico et al. The pharmacogenomics journal 2019 Feb
• MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.  
  Svrcek Magali et al. Bulletin du cancer 2019 Jan
• A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study.  
  Maeda Hiromichi et al. Oncology letters 2019 Feb 17(2) 1980-1985
• A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer.  
  Capalbo Carlo et al. Cancers 2019 Jan 11(2)